Cargando…

Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response

Neoadjuvant chemotherapy (NAC) can affect pathological complete response (pCR) in breast cancers; the resection that follows identifies patients with residual disease who are then offered second-line therapies. Circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs) in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pore, Adity A., Dhanasekara, Chathurika S., Navaid, Hunaiz Bin, Vanapalli, Siva A., Rahman, Rakhshanda Layeequr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136335/
https://www.ncbi.nlm.nih.gov/pubmed/37106672
http://dx.doi.org/10.3390/bioengineering10040485
_version_ 1785032193566834688
author Pore, Adity A.
Dhanasekara, Chathurika S.
Navaid, Hunaiz Bin
Vanapalli, Siva A.
Rahman, Rakhshanda Layeequr
author_facet Pore, Adity A.
Dhanasekara, Chathurika S.
Navaid, Hunaiz Bin
Vanapalli, Siva A.
Rahman, Rakhshanda Layeequr
author_sort Pore, Adity A.
collection PubMed
description Neoadjuvant chemotherapy (NAC) can affect pathological complete response (pCR) in breast cancers; the resection that follows identifies patients with residual disease who are then offered second-line therapies. Circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs) in the blood can be used as potential biomarkers for predicting pCR before resection. CTCs are of epithelial origin that undergo epithelial-to-mesenchymal transition to become more motile and invasive, thereby leading to invasive mesenchymal cells that seed in distant organs, causing metastasis. Additionally, CAMLs in the blood of cancer patients are reported to either engulf or aid the transport of cancer cells to distant organs. To study these rare cancer-associated cells, we conducted a preliminary study where we collected blood from patients treated with NAC after obtaining their written and informed consent. Blood was collected before, during, and after NAC, and Labyrinth microfluidic technology was used to isolate CTCs and CAMLs. Demographic, tumor marker, and treatment response data were collected. Non-parametric tests were used to compare pCR and non-pCR groups. Univariate and multivariate models were used where CTCs and CAMLs were analyzed for predicting pCR. Sixty-three samples from 21 patients were analyzed. The median(IQR) pre-NAC total and mesenchymal CTC count/5 mL was lower in the pCR vs. non-pCR group [1(3.5) vs. 5(5.75); p = 0.096], [0 vs. 2.5(7.5); p = 0.084], respectively. The median(IQR) post-NAC CAML count/5 mL was higher in the pCR vs. non-pCR group [15(6) vs. 6(4.5); p = 0.004]. The pCR group was more likely to have >10 CAMLs post-NAC vs. non-pCR group [7(100%) vs. 3(21.4%); p = 0.001]. In a multivariate logistic regression model predicting pCR, CAML count was positively associated with the log-odds of pCR [OR = 1.49(1.01, 2.18); p = 0.041], while CTCs showed a negative trend [Odds Ratio (OR) = 0.44(0.18, 1.06); p = 0.068]. In conclusion, increased CAMLs in circulation after treatment combined with lowered CTCs was associated with pCR.
format Online
Article
Text
id pubmed-10136335
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101363352023-04-28 Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response Pore, Adity A. Dhanasekara, Chathurika S. Navaid, Hunaiz Bin Vanapalli, Siva A. Rahman, Rakhshanda Layeequr Bioengineering (Basel) Article Neoadjuvant chemotherapy (NAC) can affect pathological complete response (pCR) in breast cancers; the resection that follows identifies patients with residual disease who are then offered second-line therapies. Circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs) in the blood can be used as potential biomarkers for predicting pCR before resection. CTCs are of epithelial origin that undergo epithelial-to-mesenchymal transition to become more motile and invasive, thereby leading to invasive mesenchymal cells that seed in distant organs, causing metastasis. Additionally, CAMLs in the blood of cancer patients are reported to either engulf or aid the transport of cancer cells to distant organs. To study these rare cancer-associated cells, we conducted a preliminary study where we collected blood from patients treated with NAC after obtaining their written and informed consent. Blood was collected before, during, and after NAC, and Labyrinth microfluidic technology was used to isolate CTCs and CAMLs. Demographic, tumor marker, and treatment response data were collected. Non-parametric tests were used to compare pCR and non-pCR groups. Univariate and multivariate models were used where CTCs and CAMLs were analyzed for predicting pCR. Sixty-three samples from 21 patients were analyzed. The median(IQR) pre-NAC total and mesenchymal CTC count/5 mL was lower in the pCR vs. non-pCR group [1(3.5) vs. 5(5.75); p = 0.096], [0 vs. 2.5(7.5); p = 0.084], respectively. The median(IQR) post-NAC CAML count/5 mL was higher in the pCR vs. non-pCR group [15(6) vs. 6(4.5); p = 0.004]. The pCR group was more likely to have >10 CAMLs post-NAC vs. non-pCR group [7(100%) vs. 3(21.4%); p = 0.001]. In a multivariate logistic regression model predicting pCR, CAML count was positively associated with the log-odds of pCR [OR = 1.49(1.01, 2.18); p = 0.041], while CTCs showed a negative trend [Odds Ratio (OR) = 0.44(0.18, 1.06); p = 0.068]. In conclusion, increased CAMLs in circulation after treatment combined with lowered CTCs was associated with pCR. MDPI 2023-04-18 /pmc/articles/PMC10136335/ /pubmed/37106672 http://dx.doi.org/10.3390/bioengineering10040485 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pore, Adity A.
Dhanasekara, Chathurika S.
Navaid, Hunaiz Bin
Vanapalli, Siva A.
Rahman, Rakhshanda Layeequr
Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title_full Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title_fullStr Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title_full_unstemmed Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title_short Comprehensive Profiling of Cancer-Associated Cells in the Blood of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy to Predict Pathological Complete Response
title_sort comprehensive profiling of cancer-associated cells in the blood of breast cancer patients undergoing neoadjuvant chemotherapy to predict pathological complete response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136335/
https://www.ncbi.nlm.nih.gov/pubmed/37106672
http://dx.doi.org/10.3390/bioengineering10040485
work_keys_str_mv AT poreaditya comprehensiveprofilingofcancerassociatedcellsinthebloodofbreastcancerpatientsundergoingneoadjuvantchemotherapytopredictpathologicalcompleteresponse
AT dhanasekarachathurikas comprehensiveprofilingofcancerassociatedcellsinthebloodofbreastcancerpatientsundergoingneoadjuvantchemotherapytopredictpathologicalcompleteresponse
AT navaidhunaizbin comprehensiveprofilingofcancerassociatedcellsinthebloodofbreastcancerpatientsundergoingneoadjuvantchemotherapytopredictpathologicalcompleteresponse
AT vanapallisivaa comprehensiveprofilingofcancerassociatedcellsinthebloodofbreastcancerpatientsundergoingneoadjuvantchemotherapytopredictpathologicalcompleteresponse
AT rahmanrakhshandalayeequr comprehensiveprofilingofcancerassociatedcellsinthebloodofbreastcancerpatientsundergoingneoadjuvantchemotherapytopredictpathologicalcompleteresponse